Labcorp to Acquire Select Assets of Incyte Diagnostics to Enhance Oncology Testing Services

Reuters
05-05
Labcorp to Acquire Select Assets of Incyte Diagnostics to Enhance Oncology Testing Services

Labcorp Holdings Inc., a global leader in laboratory services, has announced an agreement to acquire select assets from Incyte Diagnostics' clinical and anatomic pathology testing businesses. This transaction, expected to close later this year, includes multiple same-day testing labs and key technical assets in various locations, including Spokane, Tukwila, and Richland in Washington, as well as Missoula, Montana. The acquisition aims to enhance diagnostic services by combining Labcorp's technical expertise with Incyte's pathology proficiency. Both companies will continue operating independently until the deal's completion, ensuring no immediate changes to current operations or services. This strategic move is set to expand Labcorp's oncology testing services and its presence in the Pacific Northwest.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief on May 02, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10